OPRK1 and major depressive disorder: Aticaprant, a highly selective KOR antagonist, is currently in Phase 3 trials to assess efficacy in adults with MDD accompanied by moderate-to-severe anhedonia who have not adequately responded to current antidepressant therapy with an SSRI or SNRI.